Journal: PloS one
Article Title: ECM-dependent HIF induction directs trophoblast stem cell fate via LIMK1-mediated cytoskeletal rearrangement.
doi: 10.1371/journal.pone.0056949
Figure Lengend Snippet: Figure 3. ECM- or oxygen-dependent HIF-a subunit stabilization and TGC formation are dependent on MAP2K1/2 activity. (A) Immunoblot of whole cell lysates obtained from TSCs differentiated in 2% or 21% O2, with and without U0126, following culture on CELLstartTM, for HIF-1a, -2a or a-Tubulin. (B) Immunoblot of whole cell lysates obtained from differentiated wild-type TSCs following culture on TC plastic in Fib-CM with and without U0126 with a HIF-1a antibody. (C) (D) Immunofluorescence microscopy of TSCs maintained on CELLstartTM following differentiation for 7 days under hypoxic conditions without and with U0126 (10 uM) using anti b-Catenin antibodies (green) (blue = Dapi). (E) Quantitaive RT-PCR analysis of Plf, Pl-I, Ctsq, 4311, Mash2, Tfeb and SynA expression following differentiation of wild-type TSCs cultured on CELLstartTM under hypoxic conditions without and with U0126. p values ,0.05 versus drug free control indicated by an asterisk. (F) Immunofluorescence microscopy using anti HA (red) and b-Catenin (green) antibodies of control TSCs differentiated following culture on CELLstartTM under 21% O2 following transient tranfection with constitutively active HA:MAP2K1 or under (G) 2% O2 following transient transfection with dominant negative HA:MAP2K1. (H, I) Immunofluorescence microscopy of wild-type TSCs differentiated following culture on TC plastic in Fib-CM in 21% O2 with and without U0126 with antibodies for HDAC2 (red) and E-Cadherin (green). (J) Northern blot analysis of lineage specific marker gene expression in wild-type TSCs maintained on TC plastic in Fib-CM and differentiated with and without U0126, compared with differentiated Arnt2/2 TSCs. doi:10.1371/journal.pone.0056949.g003
Article Snippet: The following antibodies were used for immunoblotting, EMSA, immunoprecipitaion and immunofluoresence staining: CDX2 (Biogenex), EOMES (Orbigen), anti human/mouse HIF1a (R&D Systems, Minneapolis, MN), HIF-1a c-terminal (Cayman Chemical, Ann Arbor, MI), HIF-2a NB 100–122 (Novus Biologicals), ARNT 2B10 (Abcam, Cambridge, MA), pMAPK3/1 (pERK; Cell Signaling, Danvers, MA), MAPK1(ERK2; Epitomics, Burlingame, CA), a-Tubulin (NeoMarkers, Fremont, CA), Ac- a-Tubulin (Sigma-Aldrich), LIMK1 (BD Biosciences), LIMK2 (Proteintech), Cofilin (BD Biosciences), p-Cofilin (CellSignal), PDK1 (StressGen), BNIP3, VHL M-20, HOPX1 (Santa Cruz Biotechnology, Santa Cruz, CA), b-catenin (Cell Signaling), cMYC (SCBT), HA (Zymed, South San Francisco, CA), GFP (Aves), E-cadherin (BD Transduction Pharmingen), and HDAC2 (Zymed).
Techniques: Activity Assay, Western Blot, Immunofluorescence, Microscopy, Reverse Transcription Polymerase Chain Reaction, Expressing, Cell Culture, Control, Transfection, Dominant Negative Mutation, Northern Blot, Marker, Gene Expression